Mass General: Rilzabrutinib for Blood Disorder Shows Promise in Phase 1-2 Clinical Trial
April 16, 2022
April 16, 2022
BOSTON, Massachusetts, April 16 (TNSJou) -- Massachusetts General Hospital issued the following news release:
In people with immune thrombocytopenia (ITP), the body produces destructive antibodies against platelets in the blood, which increases the risk of bruising, bleeding, hospitalization, death, fatigue, and an impaired quality of life. A drug called rilzabrutinib has generated promising safety and efficacy results in a recent international multi-center phase 1-2 ITP trial led b . . .
In people with immune thrombocytopenia (ITP), the body produces destructive antibodies against platelets in the blood, which increases the risk of bruising, bleeding, hospitalization, death, fatigue, and an impaired quality of life. A drug called rilzabrutinib has generated promising safety and efficacy results in a recent international multi-center phase 1-2 ITP trial led b . . .